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ABSTRACT
Lunasin is a 44 amino acid peptide with multiple functional domains including 
an aspartic acid tail, an RGD domain, and a chromatin-binding helical domain. We 
recently showed that Lunasin induced a phenotype switch of cancer initiating cells 
(CIC) out of the stem compartment by inducing melanocyte-associated differentiation 
markers while simultaneously reducing stem-cell-associated transcription factors. 
In the present study, we advance the hypothesis that Lunasin can reduce pools 
of melanoma cells with stem cell-like properties, and demonstrate that Lunasin 
treatment effectively inhibits the invasive potential of CICs in vitro as well as in vivo 
in a mouse experimental metastasis model. Mice receiving Lunasin treatment had 
significantly reduced pulmonary colonization after injection of highly metastatic 
B16-F10 melanoma cells compared to mice in the control group. Mechanistic studies 
demonstrate that Lunasin reduced activating phosphorylations of the intracellular 
kinases FAK and AKT as well as reduced histone acetylation of lysine residues in 
H3 and H4 histones. Using peptides with mutated activity domains, we functionally 
demonstrated that the RGD domain is necessary for Lunasin uptake and its ability 
to inhibit oncosphere formation by CICs, thus confirming that Lunasin’s ability to 
affect CICs is at least in part due to the suppression of integrin signaling. Our studies 
suggest that Lunasin represents a unique anticancer agent that could be developed 
to help prevent metastasis and patient relapse by reducing the activity of CICs which 
are known to be resistant to current chemotherapies.
INTRODUCTION
Melanoma is a notoriously aggressive form of skin 
cancer that represents approximately 80% of all skin cancer 
related deaths, despite accounting for only 5% of diagnosed 
cases [1, 2]. New classes of small-molecule inhibitors 
combating malignant melanomas have yielded mixed 
results [3–5]. Although many patients achieve an initial 
tumor regression, these agents quickly become ineffective, 
and additionally, may promote the spread of a highly 
aggressive and chemoresistant population of cells [6–8]. 
Studies utilizing immunotherapy (extensively reviewed in 
[9]) to treat malignant melanomas have been found to be an 
effective treatment option; however, only a relatively small 
subset of patients achieve a sustained complete response 
[10–12]. More recently, immunotherapies with substantially 
improved objective responses in melanoma patients have 
supported the clinical utility of immunotherapy [13–16]. 
Nevertheless, adverse safety profiles, chemoresistance, and 
immune evasion continue to prove problematic in many 
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of these newly approved immunotherapies [17–19]. Thus, 
providing patients with additional novel adjuvant therapies 
to reduce or even prevent metastatic spread will continue 
to be needed for the development of effective treatment 
strategies that result in long-term survival.
The process of invasion and metastasis is perhaps 
the most significantly studied hallmark of cancer due to the 
high mortality rates caused by the metastatic dissemination 
of tumor cells from the primary tumor into distant organs. 
Malignant melanoma metastases can frequently be found 
in the brain, lymph nodes, gastrointestinal tract, liver, and 
most commonly the lungs [20]. Primary tumor formation 
and subsequent metastatic outgrowth is maintained by 
a subset of cells with innate stem cell-like abilities that 
enable them to invade and colonize surrounding tissues, 
while preserving a population of highly proliferative 
bulk tumor cells [21, 22]. The heterogeneous nature of 
melanomas make an intriguing model to study metastatic 
dissemination as they have been reported, among many 
classes of solid tumors, to harbor cancer initiating cell 
(CIC) populations identified by several biomarkers 
including aldehyde dehydrogenase (ALDH) [23, 24], 
CD20 [21], CD133 [25], CD271 [26], and ABCB5 [22].
Lunasin is a 44 amino acid peptide [27, 28] isolated 
from soy that has been shown to have chemopreventive 
and chemotherapeutic activity [29–37]. Lunasin has three 
domains implicated in its anticancer activity; an RGD 
motif, a helical domain with a sequence conserved in 
chromatin binding proteins, and a poly-aspartic acid tail 
(Figure 1). We recently reported that Lunasin significantly 
reduced a putative melanoma stem cell population 
expressing elevated levels of ALDH [37]. Additionally, 
we showed that in vivo tumor growth initiated by this 
putative CIC population was significantly impaired in 
mice treated with Lunasin. Previously, Lunasin was shown 
to inhibit metastasis of malignant colon cancer cells and 
additionally, potentiated the antimetastatic effects of 
oxaliplatin [38]; however, studies linking Lunasin to 
suppressed metastatic dissemination are largely lacking. 
With the encouraging effects of Lunasin on breast and 
melanoma CICs [37, 39], it is plausible to speculate that 
by reducing expansion of the CIC compartment, Lunasin 
would ultimately decrease the ability of tumor cells to 
invade, survive, and colonize distant tissues.
Preliminary studies of Lunasin suggested that a 
primary anticancer mechanism was derived from its 
activity as a HAT inhibitor [29]. Both HAT inhibitors and 
their counter, histone deacetylase (HDAC) inhibitors, have 
been shown to have potential clinical utility in malignant 
melanoma [40, 41]; however, these agents may also 
contribute to undesirable effects. For example, it was recently 
published the HDAC inhibitor, valproic acid, caused breast 
cancer cells to dedifferentiate toward a chemoresistant stem-
like state [42]. With regard to Lunasin, we found that histone 
acetylation patterns are altered in non-small cell lung cancer 
(NSCLC) and melanoma; however, it is an open question 
as to whether or not it is a driving mechanism in Lunasin’s 
chemotherapeutic activity. Our previous studies suggest 
that inhibition of integrin signaling is a primary mechanism 
that causes the effects seen in NSCLC models [34, 43]. The 
relationship of changes in histone acetylation and integrin 
signal transduction remains unclear. One major question that 
remains to be answered is whether integrin signaling can 
modulate epigenetic histone modifications or vice versa?
Two key signaling pathways involved in the metastatic 
cascade are the integrin-FAK axis [44] and the downstream 
PI3K/AKT pathway [45]. FAK is a critical mediator of cell 
proliferation, differentiation, angiogenesis, and invasion as it 
promotes cytoskeletal remodeling through interactions with 
several proteins including Src kinases [46]. The PI3K/AKT 
pathway is also found to be aberrantly regulated in a variety 
of cancers including melanoma [47]. Although generally 
thought of as a central protein involved in cell survival and 
cell cycling, AKT has been shown to bind and regulate FAK 
phosphorylation suggesting an important role in metastatic 
adhesion [48]. Dual targeting of these dysregulated pathways 
by disrupting upstream (integrin) signaling remains a 
promising therapeutic approach despite the fact that there are 
few clinical applications using this approach. Pharmacologic 
targeting of integrins is currently undergoing clinical trials 
for the treatment of malignant melanomas [49]. Due to 
the central role of integrins in several oncogenic signaling 
pathways [50], blockade of integrin signal transduction 
seems a likely candidate for future drug development. 
While the potential clinical benefit of integrin antagonists 
remains promising, this class of drug will likely be utilized 
in combination with more traditional chemotherapeutics 
[51–54].
Figure 1: Amino acid sequence of the Lunasin peptide. Lunasin is a 44 amino acid peptide with 3 functional domains attributed 
with its anticancer activity: 1) a helical regional conserved in chromatin-binding proteins (blue), 2) a RGD motif recognized by integrins 
(red), and 3) a poly-aspartic acid tail involved in histone-tail binding (green).
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The present study significantly extends our previous 
work by demonstrating that Lunasin inhibits metastasis-
associated activities in melanoma CICs both in vitro and 
in vivo and supports the notion that this multifaceted 
peptide with a complementary array of mechanisms has 
the potential to be used as an adjuvant therapy against 
malignant melanomas compared to single-agent treatment 
strategies.
RESULTS
Lunasin uptake correlates with expression of αV 
integrin subunits
Lunasin internalization is thought to be dependent 
upon endocytic mechanisms involving integrins [55]. 
A375 cells, which overexpress the integrin αVβ3, were 
treated with vehicle or 100 μM Lunasin, and analyzed 
for co-localization of integrin subunits and Lunasin at 
several time points ranging from 4 to 24 hours. Lunasin 
was rapidly internalized in A375 cells and was present 
both in the cytoplasm and the nucleus. Interestingly, 
cell morphology was also altered at later time points in 
Lunasin-treated cells; a decrease in cell size as well as 
localization of integrins around the nucleus was observed 
in our treated cells when compared to controls (Figure 2). 
Although Lunasin has been shown to have antiproliferative 
effects in NSCLC, we did not observe a statistically 
significant effect on cell cycle or cell viability, albeit, 
we did observe a modest increase in the G1 population; 
when A375 and B16-F10 cells were treated with Lunasin 
(Supplementary Figure 1).
B16-F10 CIC populations were reduced with 
Lunasin treatment
Previously, we showed Lunasin reduced ALDH-
expressing populations of cells in A375 and SK-MEL-28 
melanoma cell lines concomitant with a decreased 
ability of these cells to form oncospheres when plated 
in anchorage-independent culture conditions in serum-
free media [37]. To determine if this is the case with a 
murine model of melanoma, we repeated the experiments 
using the aggressive mouse-derived B16-F10 melanoma 
Figure 2: Lunasin is readily internalized by A375 melanoma cells. A375 cells treated with Lunasin for up to 24 h internalized 
Lunasin, which was found to colocalize with integrin αV subunits. Additionally, we observed nuclear localization of Lunasin that persisted 
after 24 h of treatment. We also observed the clustering of integrin subunits around the nucleus when A375 cells were treated with Lunasin 
suggesting the endocytic mechanism for Lunasin internalization involved integrins. Representative images from three independent 
experiments were used, and were taken at 40x magnification. (Blue = dapi, green = Lunasin, red = integrin αV).
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line. Representative images taken at 7 days post-treatment 
show the inhibitory effect of Lunasin on oncosphere 
formation (Figure 3A). Treatment with 100 μM Lunasin 
reduced oncosphere formation by 29% (p = 0.005, Figure 
3B). Additionally, we observed a decrease in the ALDHhigh 
population when cells were treated with 100 μM Lunasin 
for 24 h (Figure 3C and 3D). Treatment reduced the mean 
percentage of ALDH-positive B16-F10 cells from 8% in 
the control samples to 1.9% in the Lunasin-treated samples 
(p = 0.029).
Lunasin inhibits invasion of ALDHhigh melanoma 
stem cells
A375 and B16-F10 cells were sorted to isolate 
populations with elevated ALDH activity. These cells 
were pretreated with 100 μM Lunasin for 24 h, and 
subsequently replated in the upper chamber of transwell 
inserts containing serum-free DMEM/F12 media amended 
with PB or Lunasin. After adding media containing 10% 
FBS to the lower chamber, plates were incubated for 24 
h, and the cells invading through the Matrigel basement 
membrane were counted. Invasion of A375 and B16-F10 
ALDHhigh cells was significantly inhibited in Lunasin-
treated wells compared to vehicle-treated wells resulting in 
a 57% (p = 0.02) and 60% (p = 0.04) decrease in invading 
cells, respectively (Figure 4A). Representative images 
showing the Toluidine-stained invading cells from the 
bottom of the inserts illustrate the anti-migratory effects 
of Lunasin in vitro (Figure 4B).
Lunasin abrogates pulmonary metastasis in vivo
To test whether Lunasin’s antimetastatic effects 
would persist in vivo, we employed a syngeneic mouse 
model using the B16-F10 cell line. We previously 
validated this system as a model to test Lunasin’s efficacy 
in inhibiting tumor growth [56]. When 2.5x105 B16-F10 
cells were intravenously injected into C57Bl/6 mice, 
pulmonary seeding and subsequent tumor establishment 
occurred within 18 days. Throughout the experiment, mice 
were dosed daily with vehicle or Lunasin (30 mg/kg) by 
intraperitoneal (IP) injection. Upon experimental endpoint, 
we observed that Lunasin-treated mice had significantly 
reduced metastatic outgrowths when compared to control 
mice (Figure 5). Mice in the control group averaged 45 (± 
22) observable pulmonary lesions compared to only 9.5 
(± 8) in Lunasin-treated mice (Figure 5A). Representative 
images of lungs resected from metastasis-bearing mice in 
control (Figure 5C) and Lunasin (Figure 5D) treatment 
groups are shown. In addition, macrometastases were 
present in the lungs of all control mice (n = 10); however, 
Figure 3: Lunasin disrupted oncosphere formation and reduced ALDHhigh populations. B16-F10 ALDHhigh cells were plated 
in low adherent culture in stem cell media and allowed to form floating oncospheres. When media was amended with 100 μM Lunasin, we 
observed a significant decrease in oncosphere formation compared to control samples (A, B). V = vehicle, L = Lunasin. ALDH activity was 
measured as previously described. When B16-F10 cells were treated with Lunasin, we observed a significant reduction in cells displaying 
the ALDHhigh phenotype (C, D). Figures represent data obtained from three independent experiments and are shown as mean ± s.d. Statistical 
significance (p < 0.05) was determined by student’s t-test and denoted by an asterisk (*).
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Figure 4: CIC invasion was suppressed in Lunasin-treated cells. In vitro invasion assays demonstrate that Lunasin-treated 
A375 and B16-F10 ALDHhigh cells had less invasive capacity than cells treated with vehicle (A). Invading cells were stained with toluidine 
blue and representative images are shown at 20x magnification (B). Data from three independent experiments are shown as mean ± s.d. 
Statistical significance was determined by student’s t-test and denoted by an asterisk.
Figure 5: Lunasin reduced pulmonary metastases in vivo. B16-F10 melanoma cells were injected IV into female C57BL/6 mice. 
Lunasin-treated mice had less incidence of macrometastases (A) as well as significantly reduced average lesion area (B). Representative 
images of pulmonary tissues resected from control (C) and Lunasin (D) treated mice are shown. H&E stained sections demonstrate the 
significant difference between average lesion area in vehicle (E) and Lunasin (F) treated mice. Stained sections were imaged at 10x (left) 
and 40x (right), scale bar = 1 mm. Graphs represent data plotted as mean ± s.e.m. Means were determined to be statistical significant by 
student’s t-test and significance is denoted by an asterisk.
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lungs from 2 mice in the Lunasin group (n = 10) had no 
observable macrometastases (Supplementary Figure 2).
Hematoxylin and eosin (H&E) stained lung sections 
also showed an observable difference in the average area of 
micrometastases between treatment groups. Control mice 
had an average lesion area of 31.6 mm2 compared to 10.3 
mm2 in the Lunasin group (Figure 5B). Micrometastases 
formed in the lungs of vehicle treated mice (Figure 5E) 
were larger and more abundant than in mice treated with 
Lunasin (Figure 5F). Cellular morphology was similar in 
lesions found in the lungs of both control and Lunasin-
treated mice.
Lunasin antagonizes integrin signaling through 
FAK/AKT/ERK and inhibits histone acetylation
We next investigated whether the effects of Lunasin 
on human and murine melanoma cells is related to 
the known effects of Lunasin on integrin signaling and 
histone acetylation. Immunoblot analysis showed that 
A375 and B16-F10 melanoma lines treated with Lunasin 
for 24 h had decreased phosphorylation of FAK, AKT, and 
ERK. When compared to ALDHlow cells, A375 ALDHhigh 
cells showed an increased sensitivity to Lunasin’s 
disruption of AKT and ERK phosphorylation (Figure 
6A); both ALDHlow and ALDHhigh showed decreased FAK 
phosphorylation. Interestingly, ALDHhigh and ALDHlow 
A375 cells had somewhat contrasting integrin expression 
profiles; ALDHhigh cells expressed integrin subunits αV 
and β3 more abundantly than ALDH
low cells when grown 
in anchorage independent culture, while ALDHlow cells 
seemed to express higher levels of α5 and β1 integrin 
subunits (Supplementary Figure 3).
In order to extend and validate the effects of Lunasin 
on integrin signaling in CICs, we utilized proximity 
ligation assays (PLA) to investigate the interactions 
between integrin β subunits and the intracellular signal 
transducers ILK and pFAK (Y397). Initially, we observed 
that Lunasin interacts with the integrin αV subunit of A375 
ALDHhigh cells (Figure 6B). This interaction suppressed 
downstream interactions between β1 and β3 integrin 
subunits with ILK and pFAK by approximately 45% 
(Figure 6B). These results are consistent with those seen 
in our NSCLC models [34], and further confirm that the 
effects of Lunasin on melanoma CICs are, in part, due to 
altered integrin signaling pathways.
Because Lunasin has been reported to modulate 
histone acetylation, we also tested if any histone 
acetylation marks may have been altered by Lunasin 
treatment. Histones were isolated by acid extraction, and 
acetylation marks in H3 and H4 histone were assessed by 
immunoblot analysis. Previously, we identified several 
acetylation marks were altered when NSCLC cells were 
incubated with Lunasin [34]. Interestingly, we observed 
a change in a different set of acetylation marks in 
melanoma cells treated with Lunasin. Lunasin treatment 
reduced histone acetylation at H3K9 and H4K12, while 
no difference was seen in acetylation of H4K8 and H3K14 
(Figure 7A). These data indicate that Lunasin indeed 
modulates HAT activity in melanoma cells resulting in 
decreased acetylation marks, which may contribute to the 
anticancer effects of Lunasin. These changes in histone 
acetylation were concomitant with reduced FAK, AKT 
and ERK1/2 phosphorylation in Lunasin-treated A375 
and B16-F10 ALDHhigh cells. Lunasin treatment decreased 
phosphorylation of AKT at S473 and T308 as well as 
phosphorylated ERK1/2 at T202/Y204 (Figure 7B). We 
also observed that phosphorylation of FAK at tyrosine 
residues Y397 and Y925 were inhibited when ALDHhigh 
cells were treated with Lunasin for 24 h (Figure 7C). 
These results confirmed our initial data indicating that 
Lunasin significantly disrupts integrin signal transduction 
through altering phosphorylation patterns of several key 
proteins (Figure 6).
The RGD-domain is essential for Lunasin uptake 
and disrupting oncosphere formation
Our immunoblot and PLA analyses implicated 
suppression of integrin signaling and effects on histone 
acetylation as potentially being important for Lunasin 
action. To further investigate whether these mechanisms 
are required for Lunasin activity, we synthesized peptides 
in which the RGD domain or poly-aspartic acid tail 
were mutated in order to disrupt Lunasin’s interaction 
with integrins or core histones, respectively. We used 
the formation of oncospheres as a surrogate assay to 
identify the effect of Lunasin on CIC clonogenicity. We 
observed no difference in the ability of A375 ALDHhigh 
cells to form oncospheres compared to vehicle-treated 
cells and cells treated with RAD-mutated peptide (Figure 
8). Conversely, cells treated with native Lunasin (p < 
0.001) and the scrambled tail peptide (p = 0.0013) had 
a significantly reduced ability to form oncospheres in 
anchorage-independent culture (Figure 8A and 8B). These 
data suggest that the RGD domain, which interacts with 
integrins, is necessary for preventing sphere formation by 
CICs whereas the poly-aspartic acid tail is not.
An endocytic mechanism by which Lunasin is 
internalized has been reported in human macrophages 
[55]. Since the RGD domain appears to be necessary for 
Lunasin’s disruption of oncosphere formation, we next 
questioned whether or not the RGD domain was essential 
for Lunasin’s internalization. A375 cells, which express 
the RGD-recognizing integrin subunits αV and α5 (data 
not shown), were treated with 100 μM of native Lunasin 
(Figure 9A) or RAD-Lunasin (Figure 9B) for 5, 10, 30, 
and 60 minutes. Cells were fixed and probed for Lunasin 
using a rabbit polyclonal antibody which was confirmed to 
recognize the mutated peptide sequence (Supplementary 
Figure 4). Although Lunasin was detected intracellularly 
in cells treated with both native and RAD-mutated 
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Figure 6: Lunasin suppressed integrin signal transduction. ALDHhigh and ALDHlow cells derived from the A375 melanoma 
cell line were treated with 100 μM Lunasin in low adherent culture for 24 h, and the resulting lysates were probed for integrin-associated 
signaling proteins (A). We observed a significant difference in phosphorylation patterns of FAK, AKT, and ERK in ALDHhigh cells, while 
only a modest effect was observed in ALDHlow cells (A). Actin was used as a reference protein. Additionally, we used PLA assays to validate 
that Lunasin was targeting integrin signal transduction. Our results suggest Lunasin decreased the interactions between integrin β subunits 
and the intracellular kinases FAK and ILK (B). Furthermore, we show that Lunasin specifically interacts with the RGD-recognizing αV 
integrin subunit (B).
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Figure 7: Lunasin inhibited phosphorylation of FAK, AKT, and ERK as well as histone acetylation. ALDHhigh cells 
derived from human A375 and murine B16-F10 melanomas were treated with Lunasin for 24 h, and the resulting cell lysates were subjected 
to SDS-PAGE and probed for integrin-associated signaling pathways. We observed a decrease in histone acetylation at H3K9 and H4K12 
(A), which suggests epigenetic modification may play a role in Lunasin’s effects on melanoma CICs. As previously shown, these changes 
are concomitant with inhibition of activating phosphorylations of AKT (B), ERK (B), and FAK (C). Actin was used as a reference protein 
for all immunoblot analysis.
Figure 8: Lunasin’s RGD motif is essential for disrupting oncosphere formation. Mutated peptides with alterations in the 
RGD domain and the poly-aspartic-acid tail were used to treat A375 ALDHhigh cells in low adherent culture. Vehicle-treated cells readily 
formed oncospheres, but native Lunasin disrupted oncosphere formation (A). When the RGD sequence was mutated to RAD, Lunasin lost 
its ability to inhibit oncosphere formation, while a peptide containing a scrambled tail retained the ability to inhibit oncosphere generation 
(A). Representative images taken at 10x (left) and 20x (right) demonstrate the ability of the peptide to inhibit oncosphere formation (B). 
Averages from three independent experiments were plotted as mean ± s.d. Statistical significance was determined by student’s t-test and 
denoted by an asterisk.
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peptides, fluorescent intensity was much higher in cells 
treated with native Lunasin compared to RAD-Lunasin. 
Interestingly, RAD-Lunasin never localized in the nucleus 
at detectable levels, while the native peptide was observed 
in the nucleus after 10-30 minutes. These data support the 
notion that Lunasin’s internalization is largely integrin-
dependent.
DISCUSSION
Our findings that Lunasin reduced the metastatic 
potential of melanoma CICs both in vitro and in vivo 
support the earlier indications that RGD peptides may 
help alleviate patient relapse in malignant melanomas. We 
show that mechanisms previously described for Lunasin’s 
anticancer effects persist in our melanoma models, and 
perhaps most importantly, are exacerbated in isolated 
CIC populations. We showed that uptake of Lunasin in 
A375 cells was integrin-dependent and correlated with 
the expression of the integrin αV subunit. Colocalization 
of Lunasin with integrin subunits was observed at several 
time points varying from 4 h to 24 h, and localization of 
Lunasin in both the cytoplasm and nucleus was observed 
for all time points. These data are in agreement with 
previously reported studies on Lunasin’s interaction 
and uptake with specific integrin subunits [55, 57]. 
Interestingly, we observed a morphological difference 
between A375 cells treated with Lunasin and vehicle. 
Intracellular localization of integrin αV in Lunasin-treated 
cells was observed, while integrin αV was found only on 
the periphery of vehicle-treated cells. These data indicate 
that Lunasin was readily internalized in A375 cells, and 
support the previously described endocytic mechanism 
reported in human macrophages [55].
We previously published results using human 
melanoma cell lines showing that Lunasin efficiently 
reduced pools of CICs based on the ALDH biomarker, and 
resulted in disrupted oncosphere formation when ALDHhigh 
cells were plated in stem cell media in anchorage-
independent culture conditions [37]. Additionally, we 
found that Lunasin induced expression of the melanocyte-
associated differentiation markers MITF and Tyrosinase. 
Low-MITF expressing populations in melanomas 
have been described to harbor a slow cycling stem-like 
population with intrinsic chemoresistant and tumorigenic 
properties [58]. It was recently reported that MITF 
regulates melanoma invasion through Rac/Rho GTPases 
[59], which supports previous evidence showing MITF is 
explicitly involved in melanoma progression [60, 61]. This 
is a particularly interesting discovery given the regulation 
of Rac1 by integrins [62].
Figure 9: Lunasin uptake is an integrin-dependent process. RGD (A) and RAD (B) Lunasin peptides were incubated with 
A375 cells for various time points up to 1 h. While some RAD-Lunasin was detected, cells treated with RGD-Lunasin (native) showed 
significantly more abundant intracellular localization as illustrated by a significantly increased fluorescent signal. Additionally, we observed 
that native Lunasin (i.e. RGD) was localized in the nucleus of A375 cells after just 10 minutes, while RAD-Lunasin was detected mainly 
in the cytoplasm. Images are representative of data obtained from two independent experiments, and were analyzed using ImageJ software.
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In our present studies, we showed a significant 
decrease in B16-F10 oncosphere generation when treated 
with 100 μM Lunasin concomitant with a significant 
decrease in the ALDH-positive population of cells, which 
has been reported to include the CIC fraction responsible 
for tumor formation and metastasis [24]. When the in vitro 
invasive potential of A375 and B16-F10 ALDHhigh cells 
was measured, Lunasin-treated cells were significantly 
less capable of invading through an artificial basement 
membrane when compared to vehicle-treated cells. These 
data are in agreement with Lunasin’s effect on depleting 
ALDHhigh populations [37], which may be responsible for 
metastatic dissemination [23, 24, 37].
When C57Bl/6 mice were subjected to an 
experimental metastasis model of melanoma using 
B16-F10 cells, Lunasin treatment significantly suppressed 
the ability of these cells to invade and proliferate in 
the lungs. Several mice in the Lunasin-treated group 
displayed no sign of macrometastases suggesting that 
Lunasin was an effective treatment for reducing or 
abolishing metastatic burden altogether. We previously 
demonstrated that Lunasin inhibited subcutaneous tumor 
growth of murine models of melanoma and NSCLC [56]. 
Utilizing immunocompetent preclinical models of cancer 
allows researchers to explore the complex relationship 
between host immunity and tumor microenvironment; 
this especially holds true given the immunogenic nature 
of melanomas [63, 64]. It has been found that Lunasin 
may have immune boosting effects, and may improve 
vaccine efficacy by promoting dendritic cell maturation 
[65, 66]. Furthermore, Lunasin synergistically enhanced 
the cytotoxic effect of NK cells when combined with 
cytokine therapy [66]. The exciting possibility that 
Lunasin not only directly affects cells by reducing integrin 
signaling or histone acetylation, but can also “prime” the 
innate immune system to repress cancer cell proliferation 
illustrates the extremely promising benefits of this peptide 
that deserve further study.
As previously described [37], Lunasin has a 
selective effect on melanoma CICs compared to bulk 
tumor cells. We wanted to determine whether these 
selective effects would persist when integrin signal 
transduction was evaluated. Phosphorylations of FAK, 
AKT, and ERK, intracellular kinases downstream 
of integrins, were significantly reduced when A375 
and B16-F10 cells were treated with Lunasin; A more 
robust effect was observed in the ALDHhigh cells when 
compared to the ALDHlow cells. These mechanisms have 
been described in several cancer models including breast 
[36], colon [38], and lung cancer [34]; however, this is 
the first report that CICs are more sensitive to Lunasin’s 
integrin antagonism in melanoma. Given the explicit 
involvement of FAK and AKT in carcinogenesis, 
progression, and metastasis [44, 45], our results are 
promising especially taken in conjunction with our 
finding that Lunasin decreased CIC pools.
The disparate Lunasin sensitivity of A375 ALDHhigh 
and ALDHlow cells correlates with differential expression 
of specific integrin subunits when cultured as spheres 
in low-adherent conditions. ALDHhigh cells expressed 
relatively higher amounts of αV and β3 integrin subunits, 
while ALDHlow cells expressed comparatively higher 
levels of α5 and β1 integrin subunits. The complexities 
of integrin signal transduction mechanisms remain 
somewhat of a mystery, however; new research has 
revealed differences in signaling coordinated though αvβ3 
integrins and α5β1 [67, 68]. In fact, expression of specific 
integrins in stem cell-like cancer cells has been reported 
in other cancer models including prostate [69] and breast 
[70], which may reveal a potential weakness of CICs 
that provides a potential therapeutic target to specifically 
inhibit CIC expansion.
Histone acetylation by HATs (Reviewed in 
[71]) results in the unwinding of chromatin from the 
nucleosome complex consisting of H3 and H4 histones; 
efficient histone acetylation is necessary for the initiation 
of transcription of target genes. Thus, targeting HATs 
appears an attractive means to reduce cancer cell 
proliferation. Lunasin’s activity as a HAT inhibitor 
has been described [72]. Histone acetylation in A375 
and B16F10 ALDHhigh cells was affected with Lunasin 
treatment; however, Lunasin induced different acetylation 
patterns in melanoma when compared to our previously 
reported results in NSCLC [34]. Recently, it was shown 
that HAT inhibition preferentially induced apoptosis and 
inhibited stem-associated markers in a NSCLC model 
[73]. While we do not see an induction of apoptosis in our 
melanoma models, our results parallel those obtained in 
this study, suggesting a potential link between suppression 
of CIC invasion and Lunasin’s epigenetic mechanisms.
Our studies suggest that inhibition of integrin signaling 
is the primary mechanism mediating Lunasin’s effects in 
melanoma stem cells. When the RGD domain of Lunasin 
was mutated, Lunasin lost its ability to disrupt oncosphere 
formation, a surrogate assay for stem cell identification and 
propagation. Mutating the poly-aspartic acid tail seemingly 
had no effect on oncosphere formation; this implies that 
effects on histone acetylation mediated by the poly-aspartic 
acid tail are not required for inhibiting CIC clonogenicity. 
Though supporting evidence shows that stem cells can be 
maintained through integrin signaling [74], further research 
must be conducted to unequivocally determine that integrin 
antagonism is the sole mechanism for Lunasin’s reduction 
of the CIC compartment, especially given that CICs may 
also be maintained by histone acetylation [75]. This is 
particularly interesting considering that when p300, a HAT 
whose activity is antagonized by Lunasin [76], was knocked 
out in embryonic stem (ES) cells, Nanog expression was 
markedly reduced; however, self-renewal capacity (a 
function measured by oncosphere formation) was not 
significantly affected [77]. These results corroborate findings 
from our previous study [37] showing Lunasin treatment 
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resulted in a significant reduction in Nanog levels, however, 
Lunasin treatment also robustly inhibited sphere formation, 
suggesting oncosphere formation may be integrin-dependent 
and independent of histone acetylation. Crosstalk between 
integrin signaling and histone acetylation is relatively 
unexplored, however, evidence that integrin β1 engagement 
with ECM proteins may regulate H3 acetylation patterns 
has been described [78]. The complex signaling circuits 
between extracellular cues transduced through integrins, and 
intracellular events leading to changes in histone acetylation 
patterns is slowly unraveling; however, several key pieces 
of the puzzle remain to be identified. Lunasin may serve as a 
key tool to bridge the gap between these two interesting and 
highly complex signaling pathways.
In summary, the present study found that Lunasin 
has robust antimetastatic properties in vitro and in 
vivo. CICs characterized by elevated ALDH activity 
showed greater sensitivity to Lunasin’s antagonism of 
integrin signaling, as assessed by downstream activating 
phosphorylations of FAK and AKT. In agreement with our 
initial studies, we showed that B16-F10 cells exhibited 
Lunasin-dependent depletion of ALDHhigh populations, 
and disruption of oncosphere formation. While Lunasin 
also altered histone acetylation patterns, Lunasin’s effects 
in melanoma appear to be largely an integrin-dependent 
process. We extended our earlier work showing that using 
Lunasin to reduce pools of CICs may provide a new 
strategy to decrease invasion and subsequent metastatic 
outgrowths from this metastatic cell population. By 
modulating integrin signaling through FAK and PI3K/
AKT pathways as well as altering histone acetylation 
patterns, Lunasin’s complex and multifaceted anticancer 
activities suggest a potential therapeutic utility against 
malignant diseases in which recurrence due to CICs is 
likely. Given our results as well as those from others, a 
sufficient body of evidence has been obtained to justify 
further examination of the clinical utility of Lunasin as 
an anti-metastatic agent in patients with late stage cancers 
that are at risk of further metastatic dissemination.
MATERIALS AND METHODS
Purification of Lunasin from defatted soy and 
synthesis of mutated peptides
Lunasin was isolated from defatted soy flour 
as previously described [27]. Mutated peptides were 
synthesized by China Peptides (Shanghai, China) with 
purity > 95% as assessed by HPLC/MS. Full sequences 
are provided (Supplementary Figure 5). Peptides were 
dissolved in 50 mM sodium phosphate buffer pH = 7.4 
(PB) and 0.5 ml aliquots were placed into 2 kD molecular 
weight cutoff Slide-a-Lyzer cassettes (Thermo-Fisher). 
Cassettes were dialyzed against 2 liters of PB, with the 
dialysis buffer being refreshed three times over the 24 h 
dialysis period. Protein concentrations from the resulting 
dialyzed peptide solutions were determined using a 
bicinchoninic acid (BCA) assay (Pierce) following the 
manufacturer’s instructions for the microplate procedure. 
Purified bovine serum albumin (Pierce) was used as a 
standard. Peptide solutions were filter sterilized by passing 
through a 0.22 μm filter (Millipore), aliquoted, and stored 
at -20°C until use.
Cell culture and reagents
A375 and B16-F10 cells were obtained from the 
American Type Culture Collection (Rockville, MD). 
Cells were analyzed for mycoplasma contamination every 
6 months. Both cell lines were maintained in Dulbecco’s 
Modified Eagles Medium (DMEM) supplemented with 
10% Fetal Bovine Serum (FBS), Penicillin (100 U/mL), 
and Streptomycin (100 μg/mL). Cells were incubated 
at 37°C at 5% CO2 and sub-cultured every 72 hours. 
ALDHhigh cells were isolated by fluorescence-activated 
cell sorting (FACS) [37] and were grown in DMEM/F-12 
serum-free media (SFM) containing 1 × N-2 Supplement 
(Gibco) 10 ng/mL basic fibroblast growth factor (Gibco), 
and 10 ng/mL epidermal growth factor (Gibco). All 
experiments were done with cells that had been sub-
cultured from 2 to 15 passages after the initial passage 
following removal from cryostorage.
Immunofluorescence
A375 cells were plated in DMEM culture media 
at a density of 1 x 104 cells per well in an 8-chambered 
microscope slide. Cells were allowed to adhere for 4 hours 
before removal of media and replacement with media 
containing vehicle (PB) or 100 μM Lunasin. Cells were 
allowed to incubate with treatment media for up to 24 h. At 
selected times, cells were washed with PBS, fixed with 4% 
paraformaldehyde, and permeabilized with 0.1% Triton 
X-100. Cells were incubated at -20°C in 100% methanol 
before blocking with 1% bovine serum albumin. Cells were 
incubated with anti-Lunasin (1:1000) rabbit polyclonal 
antibody and anti-αV (1:100) mouse monoclonal antibody 
(Santa Cruz #376156) in blocking solution. Following 
overnight incubation, cells were washed and incubated 
with appropriate secondary antibodies conjugated to 
AlexaFluor-488 or AlexaFluor-647 fluorophores (Jackson 
ImmunoResearch). After washing, mounting media 
containing DAPI (Thermo Fisher) was dropped onto 
slides, and the slides were sealed using a 60 mm cover slip 
and clear finger nail polish prior to fluorescent analysis. 
Images were taken on a Nikon NiE upright microscope 
using Nikon Elements software (Nikon).
Proximity ligation assay (PLA)
A375 ALDHhigh cells were isolated by FACS as 
described elsewhere [37]. Briefly, cells were washed 
twice with PBS, plated on glass coverslips coated with 
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poly-lysine (Sigma), and treated with 100 μM of Lunasin 
for 24 h. After treatment, coverslips were washed and 
probed with appropriate antibodies against Lunasin, 
phosphorylated focal adhesion kinase (FAK), integrin-
linked kinase (ILK), and integrin αV and β1 subunits 
as previously described [34]. Antibodies were then 
labelled using the Duolink in situ red starter kit (Sigma) 
following the recommended manufacturer’s protocol, and 
subsequently imaged on a Nikon NiE upright microscope 
with Nikon Elements software (Nikon). Fluorescence 
analysis of at least 40 cells per sample were analyzed 
using ImageJ software (NIH).
Oncosphere formation assay
A375 and B16-F10 CICs were isolated based on 
ALDH activity as previously described [37]. Gates for each 
sample were based upon N, N-diethylaminobenzaldehyde 
(DEAB) controls for each cell line. Sorted cells were 
cultured in low-adherent 6-well plates (Corning) in serum-
free media at a density of 1 × 103cells/mL. Cultures were 
grown for up to 14 days and treated with fresh media 
containing either 100 μM Lunasin or vehicle (PB) 
twice per week. Oncospheres (> 100 μm) were counted 
and imaged using an EVOS light microscope (Life 
Technologies) and images were analyzed using Image-J 
software (NIH) as described [37].
Flow cytometry
ALDH activity was evaluated using the 
ALDEFLUORTM (StemCell Technologies) staining 
kit as described [37]. Cells were treated with vehicle 
or Lunasin for 24 h, harvested, and subjected to 
ALDEFLUOR staining. The 24 h treatment period was 
selected based on our previously published studies of 
Lunasin treatment of melanoma [37] and NSCLC [34, 
35] cells where we observed significant effects on cell 
cycle and integrin signaling. The data were analyzed 
using FlowJo V10 (FlowJo LLC) based on gates set by 
the DEAB negative control, and were kept consistent for 
all samples analyzed.
Cell cycle analysis was done by DNA staining with 
propidium iodide (PI), and analyzed using FlowJo V10 cell 
cycle analysis tool. Briefly, cells were treated for 24 h with 
vehicle or Lunasin, harvested by trypsinization, counted, 
and assessed for viability by trypan blue exclusion. 1x106 
cells were washed in PBS, and resuspended in 200 μL 
ice-cold PBS. The cell suspension was fixed by slowly 
adding the suspension drop by drop to 70% ethanol for 
rapid dispersion, and fixed overnight at -20°C. Cells were 
centrifuged, and the cell pellet was resuspended in a PI 
Master Mix (40 μg/ mL PI, 100 μg/ mL RNase, in PBS) at 
a density of 1x106 cells/ mL. Cells were incubated at 37°C 
for 30 minutes and subsequently analyzed using a FACS 
Calibur (BD Biosciences).
Transwell in vitro invasion assay
A375 and B16-F10 cells were plated in 6-well 
culture plates at a density of 1x105 cells per well in 2 mL 
of DMEM culture media. After 4 hours, the media was 
removed and replaced with media containing vehicle or 
100 μM Lunasin for 24 h. A 24 h treatment period was 
selected based on our previous studies [34, 35, 37] and 
our observation that Lunasin reduced the number of 
B16-F10 ALDHhigh cells within 24 h (Figure 3C and 3D). 
After treatment, cells were washed once with PBS, and 
harvested with TrypLE dissociation media (Gibco). Cells 
were counted and viability was assessed by trypan blue 
exclusion assay; > 95% viability was observed for all 
samples. Cells were replated at a density of 1x105 viable 
cells in serum-free DMEM culture media containing 
vehicle or Lunasin into a transwell Boyden chamber (pore 
size = 8 μm) coated with Matrigel basement membrane 
(Corning). The bottom chamber was filled with DMEM 
culture media containing 10% FBS to promote invasion 
from the top chamber. After 24 h at 37°C, cells were 
removed from the top chamber by using a cotton-tipped 
swab, and cells adhered on the bottom layer of the 
insert were fixed in 100% methanol and stained in a 1% 
Toluidine Blue in 1% borax solution. After several washes 
in distilled water, membranes were allowed to air dry, and 
mounted onto slides with immersion oil under a 60 mm 
cover slip. A total of 5 fields per insert were counted and 
averaged to obtain the average number of cells per field.
Murine model of experimental metastasis
All mice were handled in accordance with the 
Association for Assessment and Accreditation of 
Laboratory Animals Care international guidelines with 
the approval of the appropriate Institutional Animal Care 
and Use Committees at Indiana University, Bloomington 
(Protocol # 14–019–4). 2.5 x 105 B16-F10 cells suspended 
in 100 μL phosphate buffered saline (PBS) were injected 
intravenously (IV) into 20 4-6 week old, female C57Bl/6 
mice (Harlan) via the lateral tail vein. Mice were randomly 
assigned to either the control or experimental group (10 
mice/group) after receiving the initial implantation of 
B16-F10 cells. Immediately following transplantation of 
melanoma cells, mice were dosed with Lunasin (30 mg 
/ kg) or vehicle by intraperitoneal (IP) injection. The 30 
mg/kg dose was selected based on our previous in vivo 
studies of human and mouse melanoma subcutaneous 
tumor growth [37, 56]. Mice received daily IP injections 
of Lunasin or vehicle until the end of the experiment 18 
days post-transplantation of cells; preliminary studies 
demonstrated that this protocol generated numerous large 
lesions 22 days after injection. Upon sacrificing the mice, 
lungs were resected and imaged using a Leica M205 
Stereoscope (Leica). Tissues were fixed in 10% formalin 
for 72 hours and processed for subsequent histological 
staining.
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Histology
After fixation in 10% formalin, lungs were 
transferred to 70% ethanol and stored overnight at room 
temperature. Tissues were dehydrated through a series of 
graded alcohols, and infiltrated with paraffin (Electron 
Microscopy Sciences). Tissues were embedded in paraffin 
and sectioned (thickness = 7 μm) on a microtome. Sections 
were transferred to SuperFrost Plus slides (Fisher) and 
allowed to dry overnight on a slide warmer (Fisher). 
Paraffin removal was initiated by several washed in xylene, 
and followed by rehydration of the tissues in a series of 
graded alcohols. Tissues were stained in hematoxylin and 
eosin (H&E) solutions followed by a clearing solution 
of xylene. After staining, PermountTM mounting medium 
(Fisher) was applied to each slide and covered with a 60 
mm cover slip (Fisher). Slides were allowed to dry at 
room temperature overnight and then placed in a drying 
oven until completely dry. Images of H&E stained slides 
were taken using a Leica M205 Stereoscope (Leica) as 
well as an EVOS light microscope (Life Technologies). 
Macrometastases were counted under 4.32x magnification 
on the Leica M205 Stereoscope. Micrometastases were 
counted from H&E stained non-sequential sections (n = 5) 
from each tissue sample using an EVOS light microscope. 
Images were subsequently analyzed for total tumor area 
using ImageJ software (NIH).
Immunoblot analysis
Cultured cells were treated with PB or Lunasin 
(100 μM) for 24 hours. Acid extraction of histones was 
performed as described [79]. 10 μg of total purified 
histones were loaded per lane and run on 15% gels 
(Lonza). Cells were harvested and re-suspended in 
RIPA buffer (Sigma). Protein concentrations of cell 
lysates were determined by a bicinchoninic acid assay 
(Thermo Fisher Scientific) and 20–60 μg of total protein 
was loaded per lane on 10% gels (BioRad), subjected 
to SDS-PAGE, and transferred to a PVDF membrane 
(EMD Millipore). Lysates were probed with antibodies 
that recognize phosphorylated AKT (Cell Signaling 
#9916S), phosphorylated FAK (Cell Signaling #9330S), 
phosphorylated ERK 1/2 (Cell Signaling #4094), β-Actin 
(Santa Cruz #sc-47778), H3K9 (EMD Millipore #07-
352), H4K12 (EMD Millipore #04-119), H4K8 (EMD 
Millipore #07-328), H3K14 (EMD Millipore #07-353). 
Densitometry and image analysis were performed using 
a ChemiDoc station equipped with ImageLab software 
(BioRad).
Statistical analysis
GraphPad Prism 5.0 software (GraphPad Prism 
Software, Inc.) was used for all statistical analyses. For all 
in vitro studies, two-group comparisons between control 
and test samples were done by two-tailed student’s t-tests 
and represent data from three independent experiments. 
Experimental metastasis data were analyzed for 
significance using two-tailed student’s t-tests. For all tests, 
statistical significance was assumed when p < 0.05.
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